### Corporate Management Directorate



Room D3 Castle Buildings Stormont Belfast BT4 3SQ

Tel: 028 9052 0537

Text phone: 18001 028 9052 0537 Email: equality@health-ni.gov.uk

Dear Consultee Date: 24th August 2018

#### **EQUALITY SCREENING REPORT – QUARTER 1**

Please find attached the Department's quarter 1 (April– June 2018) equality screening report. The purpose of publishing the screening outcomes report is to ensure that stakeholders are aware of any final decisions in relation to completed screenings.

Also attached for your information are details of current consultations and planned consultations

Yours faithfully

932

**Judith Tener** 

# **COMPLETED SCREENINGS – QUARTER 1 (APRIL– JUNE 2018)**

- 1. "Screened in" for equality impact assessment
- 2. "screened out" with mitigation or an alternative policy proposed to be adopted
- 3. "screened out" without mitigation or an alternative policy proposed to be adopted

| Policy/Strategy                                                                                                                  | Completed  | Screening<br>Decision  1, 2 or 3 * see above | Consideration given to measures which might mitigate any adverse impact on equality of opportunity | Consideration given to alternative policies which might better achieve the promotion of equality of opportunity | Where applicable, a timetable for conducting equality impact assessments |
|----------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------------------------|----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------|
| NICE Technology Appraisal<br>TA509 - Pertuzumab with<br>trastuzumab and docetaxel for<br>treating HER2-positive breast<br>cancer | April 2018 | 3                                            | N/A                                                                                                | N/A                                                                                                             | N/A                                                                      |
| NICE Technology Appraisal<br>TA511 - Brodalumab for treating<br>moderate to severe plaque<br>psoriasis                           | April 2018 | 3                                            | N/A                                                                                                | N/A                                                                                                             | N/A                                                                      |
| NICE Technology Appraisal<br>TA513 - Obinutuzumab for<br>untreated advanced follicular<br>lymphoma                               | April 2018 | 3                                            | N/A                                                                                                | N/A                                                                                                             | N/A                                                                      |
| NICE Technology Appraisal<br>TA512 - Tivozanib for treating<br>advanced renal cell carcinoma                                     | April 2018 | 3                                            | N/A                                                                                                | N/A                                                                                                             | N/A                                                                      |

| NICE Technology Appraisal<br>TA514 - Regorafenib for<br>previously treated advanced<br>hepatocellular carcinoma                                     | April 2018 | 3 | N/A | N/A | N/A |
|-----------------------------------------------------------------------------------------------------------------------------------------------------|------------|---|-----|-----|-----|
| NICE Technology Appraisal TA515 - Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (review of TA250) | April 2018 | 3 | N/A | N/A | N/A |
| NICE Technology Appraisal<br>TA516 - Cabozantinib for treating<br>medullary thyroid cancer                                                          | April 2018 | 3 | N/A | N/A | N/A |
| NICE Clinical Guideline NG82 -<br>Age-related macular<br>degeneration                                                                               | April 2018 | 3 | N/A | N/A | N/A |
| NICE Public Health Guideline<br>NG63 - Antimicrobial<br>stewardship: changing risk-<br>related behaviours in the general<br>population              | May 2018   | 3 | N/A | N/A | N/A |
| NICE Clinical Guideline NG85 -<br>Pancreatic cancer in adults:<br>diagnosis and management                                                          | May 2018   | 3 | N/A | N/A | N/A |
| NICE Technology Appraisal<br>TA517 - Avelumab for treating<br>metastatic Merkel cell carcinoma                                                      | May 2018   | 3 | N/A | N/A | N/A |

| NICE Technology Appraisal<br>TA518 - Tocilizumab for treating<br>giant cell arteritis                                                                                                          | May 2018  | 3 | N/A | N/A | N/A |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|---|-----|-----|-----|
| NICE Clinical Guideline NG87 -<br>Attention deficit hyperactivity<br>disorder: diagnosis and<br>management (updates & replaces<br>CG72 & TA98)                                                 | June 2018 | 3 | N/A | N/A | N/A |
| NICE Technology Appraisal<br>TA520 - Atezolizumab for treating<br>locally advanced or metastatic<br>non-small-cell lung cancer after<br>chemotherapy                                           | June 2018 | 3 | N/A | N/A | N/A |
| NICE Clinical Guideline NG88 -<br>Heavy menstrual bleeding:<br>assessment and management<br>(updates & replaces CG44)                                                                          | June 2018 | 3 | N/A | N/A | N/A |
| NICE Clinical Guideline NG89 -<br>Venous thromboembolism in over<br>16s: reducing the risk of hospital-<br>acquired deep vein thrombosis or<br>pulmonary embolism (updates &<br>replaces CG92) | June 2018 | 3 | N/A | N/A | N/A |
| NICE Clinical Guideline NG95 -<br>Lyme disease                                                                                                                                                 | June 2018 | 3 | N/A | N/A | N/A |
| The Regional Co-Production Guide                                                                                                                                                               | June 2018 | 3 | N/A | N/A | N/A |

The completed screenings templates can be viewed on the Department's website at:

https://www.health-ni.gov.uk/publications/doh-policies-screened-during-period-1-april-2018-30-june-2018

If you have any difficulty accessing the internet or require this information in an alternative format please contact us at the address in the covering letter making us aware of your requirements.

### **CURRENT CONSULTATIONS**

| Policy / Strategy                                                                                                                                 | Closing Date                    |
|---------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|
| Equality and Human Rights Consultation - NICE TA - Lutetium (177lu) Oxodotreotide for Treating Unresectable or Metastatic Neuroendocrine Tumours  | 30 <sup>th</sup> August 2018    |
| Equality and Human Rights Consultation - NICE TA - Dinutuximab Beta for Treating High-Risk Neuroblastoma                                          | 30 <sup>th</sup> August 2018    |
| Equality and Human Rights Consultation - NICE TA - Lenvatinib and Sorafenib for Treating Differentiated Thyroid Cancer After Radioactive Iodine   | 30 <sup>th</sup> August 2018    |
| Equality and Human Rights Consultation - NICE TA - Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma                   | 4 <sup>th</sup> September 2018  |
| Equality and Human Rights Consultation - NICE NG 102 - Community Pharmacies: Promoting Health and Wellbeing                                       | 12 <sup>th</sup> September 2018 |
| Equality and Human Rights Consultation - NICE TA - Inotuzumab Ozogamicin for Treating Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia | 19th September 2018             |
| Equality and Human Rights Consultation - NICE NG 103 - Flu Vaccination: Increasing Uptake                                                         | 2 <sup>nd</sup> October 2018    |
| Equality and Human Rights Consultation - NICE TA - Tofacitinib for Treating Active Psoriatic Arthritis after Inadequate Response to DMARDs        | 3 <sup>rd</sup> October 2018    |
| Equality and Human Rights Consultation - NICE TA - Cabozantinib for Untreated Advanced Renal Cell Carcinoma                                       | 4 <sup>th</sup> October 2018    |

Current consultations can be viewed on the Department's website at: <a href="https://www.health-ni.gov.uk/consultations">https://www.health-ni.gov.uk/consultations</a>

## Possible future Consultations - position at August 2018 (no start dates at this time)

(\* Note: All consultations are subject to Ministerial agreement and in some case Executive approval so slippage is possible.

Consultation on Clinical Excellence Awards Scheme for 2014/15, 2015/16 and 2016/17

PSS Training Strategy 2017/2025

Information sharing for child protection purposes guidance

Consultation on proposed amendments to the Safeguarding Board for NI (Membership, Procedure, Functions and Committee) Regulations (NI) 2012

Family and parenting support strategy

Develop and consult on the principles for regulation in support of the HPSS (Quality, Improvement and Regulation) (NI) Order 2003

Local Government Reorganisation - Health and Social Care Trust Boundary Changes

Amendment to the Northern Ireland Blood Transfusion Service (Special Agency)(Establishment and Constitution) Order (NI) 1994

Develop and consult on a Looked After Children Strategy.

Proposed changes to Health Service availability of erectile dysfunction treatments

Proposed changes to the availability of Gluten Free Foods on Prescription in Primary Care

Proposed amendments to Pharmaceutical Services Regulations (NI) 1997

Misuse of Drugs Safe Custody Regulations consolidation

Proposal to remove the statutory requirement to maintain Addicts Index

To consult on proposals to introduce Minimum Unit Pricing of Alcohol

Updated minimum care standards for residential homes

Service framework for mental health and wellbeing

Consultation on changes to terms of service for opticians

GP Federations policy statement and legal status of GP Federations

Consultation on the Department's response to the report by the Expert Advisory Panel on Adult Care and Support

Regulations to be made under Health and Social care

(Control of data processing) Act (NI) 2016

Consultation on amendments to the Firefighters Pension Schemes re Survivors Benefits

Consultation on Code of Practice, Regulations and scenarios for Mental Capacity Act (NI) 2016

Consultation on a new public health/health protection bill that will aim to enable responsible bodies to provide a response to infectious disease, contamination or other such hazards which constitute a danger to human health

Consultation on draft principles to underpin the primary care multi-disciplinary teams model

You may be interested in the upcoming UK Wide consultations below

Misuse of Drugs Safe Custody Regulations Consolodation